ATNM — Actinium Pharmaceuticals, Inc.

—

NYSE · Health Care · Pharmaceuticals · CIK 1388320 ·

Last close

$1.02

Market Cap

$32.00M

52W High

$1.53

52W Low

$0.95

ADV30

129,364

Next earnings

—

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

Period	Revenues	GrossProfit	OpIncome	NetIncome	Assets	Cash	Liabilities
Mar 2026	0	—	-5,903,000	-5,522,000	45,438,000	42,132,000	43,134,000
Dec 2025	0	—	-6,414,000	-5,940,000	51,775,000	47,998,000	43,941,000
Sep 2025	90,000	—	-5,692,000	-5,131,000	56,151,000	53,391,000	42,367,000
Jun 2025	0	—	-7,503,000	-6,878,000	63,017,000	59,928,000	44,004,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF

$-24,580,000

Investing CF

$-104,000

Financing CF

$-217,000

CapEx

—

Dividends Paid

—

Buybacks

—

EPS Diluted TTM

$-1.26

As of

2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings

$-409,713,000

Inventory

—

Receivables

—

ST Investments

—

EBIT TTM

$-36,247,000

Pretax Income TTM

$-33,887,000

Interest Exp TTM

—

Analysts

Yahoo Snapshot (yfinance, live)

Total Revenue

$90,000

EBITDA

$-25,347,000

Free Cash Flow

$-14,791,000

Enterprise Value

$-9,865,509

Total Cash

$42,132,000

Total Debt

$1,519,000

Shares Out

31,374,994

Trailing EPS

$-0.76

Book Value

$0.07

ROE

-167.7%

ROA

-28.0%

Div Yield

—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY end	Revenues	OpIncome	NetIncome	Assets	Liabilities	Equity	OCF
Dec 2025	90,000	-36,247,000	-33,887,000	51,775,000	43,941,000	—	-24,580,000
Dec 2024	0	-42,121,000	-38,243,000	76,899,000	44,141,000	—	-33,072,000
Dec 2023	81,000	-51,920,000	-48,818,000	81,445,000	45,066,000	—	-47,335,000
Dec 2022	1,030,000	-34,104,000	-33,017,000	114,192,000	47,711,000	—	8,644,000

TTM Snapshot

Revenues TTM

—

NetIncome TTM

—

OpCashFlow TTM

—

Assets (Latest)

—

Forward EPS

$-0.35

Peers — same industry

Ticker	Name	Market Cap	Last	Daily %
LSTA	LISATA THERAPEUTICS, INC.	$32.05M	$3.52	—
SDEV	Stablecoin Development Corp	$32.27M	$1.19	—
BOLD	Boundless Bio, Inc.	$31.45M	$1.40	—
LITS	Lite Strategy, Inc.	$31.28M	$0.92	—
DARE	Dare Bioscience, Inc.	$31.16M	$2.08	—

News headlines (Yahoo Finance, 1h cache)

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

2026-06-03 12:00 · Yahoo

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros

2026-06-03 11:25 · Yahoo

Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development

2026-06-01 12:00 · Yahoo

Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates

2026-06-01 11:00 · Yahoo

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

2026-05-29 21:31 · Yahoo

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

2026-05-29 21:30 · Yahoo

Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization

2026-05-06 12:00 · Yahoo

Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting

2026-04-22 11:00 · Yahoo

Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer